HeartBeam Inc. Reports Q3 2025 Earnings and Forecasts
HeartBeam Inc. (ticker BEAT) announced its third‑quarter 2025 financial results on November 13, 2025 through a live earnings call transcript released by Fool.com. The company, which specializes in telemedicine solutions for remote detection and monitoring of cardiac disease, has been operating under the Nasdaq symbol BEAT and is headquartered in Santa Clara, United States.
Key Highlights from the Earnings Call
| Item | Detail |
|---|---|
| Revenue | $0.9 million (Q3 2025) |
| Earnings per Share | -0.129 USD (average analyst forecast) |
| Year‑over‑Year Comparison | Revenue up from $0.0 million in the same period a year earlier; EPS loss narrowed from -0.190 USD to -0.129 USD |
| Guidance | Analysts expect the next quarter to see continued revenue growth as HeartBeam expands its patient base and refines its AI‑driven monitoring algorithms. |
The company’s management emphasized that the Q3 figures demonstrate a steady improvement in operational efficiency and a significant reduction in per‑patient costs, a trend that aligns with its mission to make cardiovascular monitoring more accessible outside traditional healthcare settings.
Market Reaction
- The stock closed at $1.67 on November 11, 2025, trading within a 52‑week range of $0.91 to $3.48.
- The market capitalization stood at $57.3 million USD, reflecting modest investor confidence given the company’s negative price‑earnings ratio of -1.72.
- Following the earnings release, analysts noted that while the company remains unprofitable, the loss per share has improved, which may support a bullish outlook if future quarters continue to close the gap to profitability.
Contextualizing the Results
HeartBeam’s quarterly performance comes at a time when the broader health‑tech sector is seeing heightened interest in remote monitoring solutions. The company’s focus on telemedicine for cardiac diseases positions it uniquely to capture demand from patients and clinicians seeking non‑in‑hospital care pathways.
Despite the negative earnings, the revenue growth and declining loss suggest that the company’s business model is gaining traction. Management highlighted ongoing partnerships and product enhancements that could accelerate adoption, especially as regulatory environments become more conducive to AI‑driven diagnostics.
Conclusion
HeartBeam Inc. has delivered a positive trajectory in revenue and earnings per share for the third quarter of 2025. While the company continues to operate at a loss, the narrowing of its negative EPS and the upward revision of revenue expectations signal progress toward operational sustainability. Investors and analysts will likely watch the next earnings cycle closely to gauge whether HeartBeam can transition from a growth phase to a profitable, scalable enterprise.
